Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi.
Under this rolling submission, the US FDA will review data as and when it becomes available until they have received enough data for a formal marketing application.
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody (mAb) for the treatment of Alzheimer’s disease. In January 2023, it was granted accelerated approval by the US FDA. Leqembi targets the fundamental pathophysiology of the disease, and has demonstrated statistically significant reductions in brain amyloid plaque in patients with mild cognitive impairment and confirmed presence of amyloid beta pathology. Amyloid beta deposits are a histopathological hallmark of Alzheimer’s disease. Currently, it is administered via intravenous infusion bi-weekly.
In April, Eisai delayed filing for marketing approval of a subcutaneous form of Leqembi when the FDA requested 3-month additional immunogenicity data. The hope is that, should the subcutaneous form be approved, patients can be treated at home or at non-clinical medical facilities as it is less invasive and time-consuming than the intravenous formulation. The intravenous formulation also requires certain pre-requisites from patients, such as additional diagnostic tests and twice-monthly infusions and regular brain scans.
Sales of Leqembi are projected to increase 13-fold in 2024 from the fiscal year-end of March. Eisai plans to launch Leqembi in China in July, and expects most sales growth to come from the US market.
Source:
Eisai starts rolling submission for injectable version of Alzheimer’s drug with US FDA [Accessed May 15, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-starts-rolling-submission-injectable-version-alzheimers-drug-with-us-fda-2024-05-14/
Related News
-
News Racial disparities in diagnosis and drug use for dementia symptoms
A study from the USC Schaeffer Center for Health Policy & Economics has revealed the existence of racial disparities in the US for the diagnosis of dementia and the use of drug treatments for symptoms. -
News MDMA-assisted therapy for PTSD to be reviewed by US FDA
American public benefit corporation (PBC) Lykos Therapeutics have announced that the US FDA Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting their new drug application (NDA) for MDMA capsules, which are to be used in comb... -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News Pharma giants battle over COVID-19 patents in London courts
Two key players in the COVID-19 vaccine story – Pfizer/BioNTech and Moderna – have begun the latest chapter of their global legal battle over patents concerning technology for the development of mRNA therapeutics such as the COVID-19 vaccin... -
News Women in Pharma: Diversi‘tea’ at CPHI North America
CPHI North America will unite the pharmaceutical supply chain in Philadelphia from May 7–9, 2024 for 3 days of innovation and connections. As part of the content Agenda, our Diversity Track will bring the industry together to discuss the imperati... -
News CPHI Online Webinar Series – Optimising Pharma Manufacturing through Digital Transformations
This month’s CPHI Webinar Series explored achieving manufacturing excellence in pharma through the digitalisation of daily processes. Presented by Joe Doyle, Head of Sales at EviView, and Bikash Chatterjee, President and Chief Scientific Off... -
News Western pharma groups warn of supply disruptions over China anti-spy law
China’s anti-espionage laws have caused concern among western pharmaceutical groups over potential arrests or denial of access for foreign inspectors in China-based facilities and manufacturing partners, posing a risk to the supply of drug produc... -
News More to celebrate at the CPHI Milan Pharma Awards 2024
The CPHI Milan Pharma Awards, which are now open for nominations until 18 May 2024, celebrate the innovators making a difference. This year, two new categories have been added to further honour the contributions of a diverse range of pharma professiona...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance